Shopping Cart 0
Cart Subtotal
USD 0

Vascular Grafts - Medical Devices Pipeline Assessment, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 4000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 8000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 12000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Vascular Grafts-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Vascular Grafts-Medical Devices Pipeline Assessment, 2018 provides an overview of Vascular Grafts currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vascular Grafts pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Vascular Grafts under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Vascular Grafts and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Vascular Grafts under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Vascular Grafts Overview 8

3 Products under Development 9

3.1 Vascular Grafts-Pipeline Products by Stage of Development 9

3.2 Vascular Grafts-Pipeline Products by Segment 10

3.3 Vascular Grafts-Pipeline Products by Territory 11

3.4 Vascular Grafts-Pipeline Products by Regulatory Path 12

3.5 Vascular Grafts-Pipeline Products by Estimated Approval Date 13

3.6 Vascular Grafts-Ongoing Clinical Trials 14

4 Vascular Grafts-Pipeline Products under Development by Companies 15

4.1 Vascular Grafts Companies-Pipeline Products by Stage of Development 15

4.2 Vascular Grafts-Pipeline Products by Stage of Development 17

5 Vascular Grafts Companies and Product Overview 18

5.1 Ariste Medical LLC Company Overview 18

5.1.1 Ariste Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 18

5.2 BioSurfaces, Inc. Company Overview 19

5.2.1 BioSurfaces, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19

5.3 Cardiojustable LLC (Inactive) Company Overview 20

5.3.1 Cardiojustable LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 20

5.4 Cardiovate Company Overview 21

5.4.1 Cardiovate Pipeline Products & Ongoing Clinical Trials Overview 21

5.5 Colorado Therapeutics, LLC Company Overview 22

5.5.1 Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview 22

5.6 CryoLife Inc Company Overview 23

5.6.1 CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview 23

5.7 Cytograft Tissue Engineering Inc (Inactive) Company Overview 24

5.7.1 Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24

5.8 DSM Biomedical BV Company Overview 26

5.8.1 DSM Biomedical BV Pipeline Products & Ongoing Clinical Trials Overview 26

5.9 Eqalix Inc Company Overview 27

5.9.1 Eqalix Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.10 FIT Biotech Oy Company Overview 29

5.10.1 FIT Biotech Oy Pipeline Products & Ongoing Clinical Trials Overview 29

5.11 Gel-Del Technologies, Inc. Company Overview 31

5.11.1 Gel-Del Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31

5.12 Humacyte Inc Company Overview 32

5.12.1 Humacyte Inc Pipeline Products & Ongoing Clinical Trials Overview 32

5.13 Innovia LLC Company Overview 36

5.13.1 Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 36

5.14 LeMaitre Vascular Inc Company Overview 37

5.14.1 LeMaitre Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 37

5.15 Merit Medical Systems Inc Company Overview 39

5.15.1 Merit Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 39

5.16 Northwestern University Company Overview 40

5.16.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 40

5.17 Peca Labs, Inc. Company Overview 41

5.17.1 Peca Labs, Inc. Pipeline Products & Ongoing Clinical Trials Overview 41

5.18 PetVivo Holdings Inc Company Overview 42

5.18.1 PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 42

5.19 RegenaGraft Company Overview 43

5.19.1 RegenaGraft Pipeline Products & Ongoing Clinical Trials Overview 43

5.20 Secant Group LLC Company Overview 44

5.20.1 Secant Group LLC Pipeline Products & Ongoing Clinical Trials Overview 44

5.21 Terumo Aortic Company Overview 45

5.21.1 Terumo Aortic Pipeline Products & Ongoing Clinical Trials Overview 45

5.22 TTK Healthcare Ltd Company Overview 46

5.22.1 TTK Healthcare Ltd Pipeline Products & Ongoing Clinical Trials Overview 46

5.23 Universidad de Los Andes Company Overview 47

5.23.1 Universidad de Los Andes Pipeline Products & Ongoing Clinical Trials Overview 47

5.24 University of Louisville Company Overview 48

5.24.1 University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 48

5.25 University of Pittsburgh Company Overview 49

5.25.1 University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 49

5.26 VA Boston Healthcare System Company Overview 50

5.26.1 VA Boston Healthcare System Pipeline Products & Ongoing Clinical Trials Overview 50

5.27 VesselTek BioMedical LLC Company Overview 51

5.27.1 VesselTek BioMedical LLC Pipeline Products & Ongoing Clinical Trials Overview 51

5.28 VESSL Therapeutics Ltd Company Overview 52

5.28.1 VESSL Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview 52

5.29 W. L. Gore & Associates Inc Company Overview 53

5.29.1 W. L. Gore & Associates Inc Pipeline Products & Ongoing Clinical Trials Overview 53

5.30 Xeltis AG Company Overview 56

5.30.1 Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview 56

6 Vascular Grafts- Recent Developments 57

6.1 May 17, 2018: Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC 57

6.2 May 02, 2018: CryoLife Announces First Quarter 2018 Financial Results 57

6.3 Apr 27, 2018: Fit Biotech: Appointment of Tommi Holopainen as CFO and as a Member of the Management Team 58

6.4 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018 59

6.5 Apr 25, 2018: LeMaitre Q1 2018 Sales USD26.0mm (+8%), EPS USD0.19 (+17%) 61

6.6 Mar 28, 2018: MicroPort Scientific Announces 2017 Annual Results 61

6.7 Mar 27, 2018: MicroPort Scientific Announces Year Ended 31 December 2017 Financial Results 63

6.8 Mar 15, 2018: FIT Biotech's Review of Operations and Financial Statement 2017 published 64

6.9 Mar 07, 2018: CryoLife Reports Fourth Quarter and Full Year 2017 Results 64

6.10 Feb 21, 2018: LeMaitre Reports Net Income Of USD4.3mm In Q4 2017 65

6.11 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 66

6.12 Jan 23, 2018: Jonathan Vande Geest, University Of Pittsburg Has Received A NIH Grant To Construct A Biomeimetic, Small Diameter Vascular Graft 68

6.13 Jan 18, 2018: FIT Biotech's CEO to change-Erkki Pekkarinen appointed as a new CEO 68

6.14 Jan 18, 2018: FIT Biotech Oy Announces Senior Management Changes 69

6.15 Jan 16, 2018: Secant Group Develops the First Synthetic Regenerative Cardiovascular Graft 69

6.16 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 70

6.17 Oct 30, 2017: CryoLife Reports Third Quarter 2017 Results 70

6.18 Oct 26, 2017: LeMaitre Q3 2017 Sales USD24.8mm (+7%), Record EPS USD0.25 (+49%) 72

6.19 Oct 26, 2017: Boston Scientific Announces Results For Third Quarter 2017 72

6.20 Oct 25, 2017: Bard Announces Third Quarter Results 74

6.21 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary 75

6.22 Oct 02, 2017: Humacyte Awarded USD3.4 Million Contract Award from the U.S. Department of Defense 76

6.23 Oct 02, 2017: Jeffrey H. Burbank Joins CryoLife Board of Directors 76

6.24 Sep 26, 2017: ETR featured in peer-reviewed journal EuroIntervention 77

6.25 Sep 22, 2017: Xeltis CTO on the future of heart valve therapy at PCR London Valves 77

6.26 Sep 15, 2017: Fit Biotech Half-yearly Financial Report January 1-June 30, 2017 78

6.27 Sep 11, 2017: MPSC Achieves Substantial Growth in 1H 2017 Net Profit Increases 272.4% YOY 78

6.28 Aug 23, 2017: FIT Biotech Oy: FIT Biotech Board elected Erkki Pekkarinen to the Deputy Chairman of the Board 80

6.29 Aug 14, 2017: Governor McAuliffe Announces LifeNet Health to Invest USD12.25 million, Create 321 New Jobs in City of Virginia Beach 80

6.30 Aug 11, 2017: MPSC Issues Positive Profit Alert for 2017 1H Net Profit Expected to Increase 261% 81

6.31 Jul 27, 2017: LeMaitre Q2 2017 Record Sales USD25.8 mm (+15%), Record EPS USD0.23 (+69%) 81

6.32 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 82

6.33 Jul 24, 2017: MicroPort Attends EUROPACE-CARDIOSTIM 2017 84

6.34 Jul 24, 2017: CryoLife Reports Second Quarter 2017 Financial Results 84

6.35 Jul 20, 2017: Positive progression of ETR clinical trials at WCPCCS 86

6.36 Jul 07, 2017: MPSC New COO Glendy Wang on Board 86

6.37 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 86

7 Appendix 89

7.1 Methodology 89

7.2 About GlobalData 92

7.3 Contact Us 92

7.4 Disclaimer 92


List Of Figure

1.2 List of Figures

Figure 1: Vascular Grafts-Pipeline Products by Stage of Development 9

Figure 2: Vascular Grafts-Pipeline Products by Segment 10

Figure 3: Vascular Grafts-Pipeline Products by Territory 11

Figure 4: Vascular Grafts-Pipeline Products by Regulatory Path 12

Figure 5: Vascular Grafts-Pipeline Products by Estimated Approval Date 13

Figure 6: Vascular Grafts-Ongoing Clinical Trials 14


List Of Table

1.1 List of Tables

Table 1: Vascular Grafts-Pipeline Products by Stage of Development 9

Table 2: Vascular Grafts-Pipeline Products by Segment 10

Table 3: Vascular Grafts-Pipeline Products by Territory 11

Table 4: Vascular Grafts-Pipeline Products by Regulatory Path 12

Table 5: Vascular Grafts-Pipeline Products by Estimated Approval Date 13

Table 6: Vascular Grafts-Ongoing Clinical Trials 14

Table 7: Vascular Grafts Companies-Pipeline Products by Stage of Development 15

Table 8: Vascular Grafts-Pipeline Products by Stage of Development 17

Table 9: Ariste Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 18

Table 10: Drug Eluting Vascular Graft-Product Status 18

Table 11: Drug Eluting Vascular Graft-Product Description 18

Table 12: BioSurfaces, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19

Table 13: BioFunc-APC Vascular Graft-Product Status 19

Table 14: BioFunc-APC Vascular Graft-Product Description 19

Table 15: Cardiojustable LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 20

Table 16: Adjustable SPA Shunt-Product Status 20

Table 17: Adjustable SPA Shunt-Product Description 20

Table 18: Cardiovate Pipeline Products & Ongoing Clinical Trials Overview 21

Table 19: NeoVessel Vascular Graft-Product Status 21

Table 20: NeoVessel Vascular Graft-Product Description 21

Table 21: Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview 22

Table 22: Xenograft Implant-Peripheral Vascular Disease-Product Status 22

Table 23: Xenograft Implant-Peripheral Vascular Disease-Product Description 22

Table 24: CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview 23

Table 25: Synergraft Xenograft Vascular Graft-Product Status 23

Table 26: Synergraft Xenograft Vascular Graft-Product Description 23

Table 27: Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24

Table 28: Lifeline TEBV-Lower Limb-Product Status 24

Table 29: Lifeline TEBV-Lower Limb-Product Description 24

Table 30: LifeLine TEBV-Pediatric-Product Status 25

Table 31: LifeLine TEBV-Pediatric-Product Description 25

Table 32: DSM Biomedical BV Pipeline Products & Ongoing Clinical Trials Overview 26

Table 33: Small Diameter Vascular Graft-Product Status 26

Table 34: Small Diameter Vascular Graft-Product Description 26

Table 35: Eqalix Inc Pipeline Products & Ongoing Clinical Trials Overview 27

Table 36: CardioVessel-Product Status 27

Table 37: CardioVessel-Product Description 27

Table 38: LCL Graft-Product Status 28

Table 39: LCL Graft-Product Description 28

Table 40: FIT Biotech Oy Pipeline Products & Ongoing Clinical Trials Overview 29

Table 41: GTU X-Graft-Product Status 29

Table 42: GTU X-Graft-Product Description 29

Table 43: GTU X2-Graft-Product Status 30

Table 44: GTU X2-Graft-Product Description 30

Table 45: Gel-Del Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31

Table 46: VasoGraft-Product Status 31

Table 47: VasoGraft-Product Description 31

Table 48: Humacyte Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Table 49: HUMACYL-Peripheral Artery Disease-Product Status 32

Table 50: HUMACYL-Peripheral Artery Disease-Product Description 32

Table 51: HUMACYL Graft-Vascular Trauma-Product Status 33

Table 52: HUMACYL Graft-Vascular Trauma-Product Description 33

Table 53: Humacyte Inc-Ongoing Clinical Trials Overview 34

Table 54: HUMACYL-Peripheral Artery Disease-A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacytes Human Acellular Vessel for Use as a Vascular Bypass or Interposition Vessel in Patients with Limb-threatening Peripheral Arterial Trauma 35

Table 55: Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 36

Table 56: 4mm Vascular Graft-Product Status 36

Table 57: 4mm Vascular Graft-Product Description 36

Table 58: LeMaitre Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 37

Table 59: LifeSpan ePTFE Vascular Graft-Product Status 37

Table 60: LifeSpan ePTFE Vascular Graft-Product Description 38

Table 61: Merit Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 39

Table 62: Self-expanding Covered Stent Graft-Product Status 39

Table 63: Self-expanding Covered Stent Graft-Product Description 39

Table 64: Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 40

Table 65: ePTFE Graft-Peripheral Arterial Disease-Product Status 40

Table 66: ePTFE Graft-Peripheral Arterial Disease-Product Description 40

Table 67: Peca Labs, Inc. Pipeline Products & Ongoing Clinical Trials Overview 41

Table 68: exGraft-Product Status 41

Table 69: exGraft-Product Description 41

Table 70: PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 42

Table 71: Peripheral Vascular Graft-Product Status 42

Table 72: Peripheral Vascular Graft-Product Description 42

Table 73: RegenaGraft Pipeline Products & Ongoing Clinical Trials Overview 43

Table 74: RegenaVasc-Product Status 43

Table 75: RegenaVasc-Product Description 43

Table 76: Secant Group LLC Pipeline Products & Ongoing Clinical Trials Overview 44

Table 77: Regenerative Cardiovascular Graft-Product Status 44

Table 78: Regenerative Cardiovascular Graft-Product Description 44

Table 79: Terumo Aortic Pipeline Products & Ongoing Clinical Trials Overview 45

Table 80: Triplex Advanced Vascular Graft-Product Status 45

Table 81: Triplex Advanced Vascular Graft-Product Description 45

Table 82: TTK Healthcare Ltd Pipeline Products & Ongoing Clinical Trials Overview 46

Table 83: Chitra Vascular Graft-Product Status 46

Table 84: Chitra Vascular Graft-Product Description 46

Table 85: Universidad de Los Andes Pipeline Products & Ongoing Clinical Trials Overview 47

Table 86: SiSgraft-Product Status 47

Table 87: SiSgraft-Product Description 47

Table 88: University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 48

Table 89: Vascular Graft System-Product Status 48

Table 90: Vascular Graft System-Product Description 48

Table 91: University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 49

Table 92: Biomimetic Vascular Graft-Product Status 49

Table 93: Biomimetic Vascular Graft-Product Description 49

Table 94: VA Boston Healthcare System Pipeline Products & Ongoing Clinical Trials Overview 50

Table 95: SelfWrap-Product Status 50

Table 96: SelfWrap-Product Description 50

Table 97: VesselTek BioMedical LLC Pipeline Products & Ongoing Clinical Trials Overview 51

Table 98: VTek Graft-Product Status 51

Table 99: VTek Graft-Product Description 51

Table 100: VESSL Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview 52

Table 101: MultiGeneGraft-Product Status 52

Table 102: MultiGeneGraft-Product Description 52

Table 103: W. L. Gore & Associates Inc Pipeline Products & Ongoing Clinical Trials Overview 53

Table 104: GORE VIABAHN Endoprosthesis-Product Status 53

Table 105: GORE VIABAHN Endoprosthesis-Product Description 53

Table 106: W. L. Gore & Associates Inc-Ongoing Clinical Trials Overview 54

Table 107: GORE VIABAHN Endoprosthesis-Post-approval Study of the Gore Viabahn Endoprosthesis for the Treatment of In-stent Restenosis (ISR) in the Superficial Femoral Artery (SFA) 55

Table 108: GORE VIABAHN Endoprosthesis-Post-market Study: Evaluation of the GORE VIABAHN Endoprosthesis for the Treatment of Popliteal Artery Aneurysm 55

Table 109: GORE VIABAHN Endoprosthesis-The Utility of GP1101 Relative to Surgical Bypass in the Treatment of Femoral / Popliteal Arterial Symptomatic Peripheral Arterial Disease 55

Table 110: Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview 56

Table 111: Endogenous Tissue Restoration (ETR) Cardiovascular Graft-Product Status 56

Table 112: Endogenous Tissue Restoration (ETR) Cardiovascular Graft-Product Description 56

Table 113: Glossary 91

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Ariste Medical LLC, Drug Eluting Vascular Graft; BioSurfaces, Inc., BioFunc - APC Vascular Graft; Cardiojustable LLC (Inactive), Adjustable SPA Shunt; Cardiovate, NeoVessel Vascular Graft; Colorado Therapeutics, LLC, Xenograft Implant - Peripheral Vascular Disease; CryoLife Inc, Synergraft Xenograft Vascular Graft; Cytograft Tissue Engineering Inc (Inactive), Lifeline TEBV - Lower Limb; Cytograft Tissue Engineering Inc (Inactive), LifeLine TEBV - Pediatric; DSM Biomedical BV, Small Diameter Vascular Graft; Eqalix Inc, CardioVessel; Eqalix Inc, LCL Graft; FIT Biotech Oy, GTU X2-Graft; FIT Biotech Oy, GTU X-Graft; Gel-Del Technologies, Inc., VasoGraft; Humacyte Inc, HUMACYL - Peripheral Artery Disease; Humacyte Inc, HUMACYL Graft - Vascular Trauma; Innovia LLC, 4mm Vascular Graft; LeMaitre Vascular Inc, LifeSpan ePTFE Vascular Graft; Merit Medical Systems Inc, Self-expanding Covered Stent Graft; Northwestern University, ePTFE Graft - Peripheral Arterial Disease; Peca Labs, Inc., exGraft; PetVivo Holdings Inc, Peripheral Vascular Graft; RegenaGraft, RegenaVasc; Secant Group LLC, Regenerative Cardiovascular Graft; Terumo Aortic, Triplex Advanced Vascular Graft; TTK Healthcare Ltd, Chitra Vascular Graft; Universidad de Los Andes, SiSgraft; University of Louisville, Vascular Graft System; University of Pittsburgh, Biomimetic Vascular Graft; VA Boston Healthcare System, SelfWrap; VesselTek BioMedical LLC, VTek Graft; VESSL Therapeutics Ltd, MultiGeneGraft; W. L. Gore &; Associates Inc, GORE VIABAHN Endoprosthesis; Xeltis AG, Endogenous Tissue Restoration (ETR) Cardiovascular Graft


Companies

Ariste Medical LLC

BioSurfaces, Inc.

Cardiojustable LLC

Cardiovate

Colorado Therapeutics, LLC

CryoLife Inc

Cytograft Tissue Engineering Inc

DSM Biomedical BV

Eqalix Inc

FIT Biotech Oy

Gel-Del Technologies, Inc.

Humacyte Inc

Innovia LLC

LeMaitre Vascular Inc

Merit Medical Systems Inc

Northwestern University

Peca Labs, Inc.

PetVivo Holdings Inc

RegenaGraft

Secant Group LLC

Terumo Aortic

TTK Healthcare Ltd

Universidad de Los Andes

University of Louisville

University of Pittsburgh

VA Boston Healthcare System

VesselTek BioMedical LLC

VESSL Therapeutics Ltd

W. L. Gore & Associates Inc

Xeltis AG

Vascular Grafts-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Vascular Grafts-Medical Devices Pipeline Assessment, 2018 provides an overview of Vascular Grafts currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vascular Grafts pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Vascular Grafts under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Vascular Grafts and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Vascular Grafts under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Vascular Grafts Overview 8

3 Products under Development 9

3.1 Vascular Grafts-Pipeline Products by Stage of Development 9

3.2 Vascular Grafts-Pipeline Products by Segment 10

3.3 Vascular Grafts-Pipeline Products by Territory 11

3.4 Vascular Grafts-Pipeline Products by Regulatory Path 12

3.5 Vascular Grafts-Pipeline Products by Estimated Approval Date 13

3.6 Vascular Grafts-Ongoing Clinical Trials 14

4 Vascular Grafts-Pipeline Products under Development by Companies 15

4.1 Vascular Grafts Companies-Pipeline Products by Stage of Development 15

4.2 Vascular Grafts-Pipeline Products by Stage of Development 17

5 Vascular Grafts Companies and Product Overview 18

5.1 Ariste Medical LLC Company Overview 18

5.1.1 Ariste Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 18

5.2 BioSurfaces, Inc. Company Overview 19

5.2.1 BioSurfaces, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19

5.3 Cardiojustable LLC (Inactive) Company Overview 20

5.3.1 Cardiojustable LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 20

5.4 Cardiovate Company Overview 21

5.4.1 Cardiovate Pipeline Products & Ongoing Clinical Trials Overview 21

5.5 Colorado Therapeutics, LLC Company Overview 22

5.5.1 Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview 22

5.6 CryoLife Inc Company Overview 23

5.6.1 CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview 23

5.7 Cytograft Tissue Engineering Inc (Inactive) Company Overview 24

5.7.1 Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24

5.8 DSM Biomedical BV Company Overview 26

5.8.1 DSM Biomedical BV Pipeline Products & Ongoing Clinical Trials Overview 26

5.9 Eqalix Inc Company Overview 27

5.9.1 Eqalix Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.10 FIT Biotech Oy Company Overview 29

5.10.1 FIT Biotech Oy Pipeline Products & Ongoing Clinical Trials Overview 29

5.11 Gel-Del Technologies, Inc. Company Overview 31

5.11.1 Gel-Del Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31

5.12 Humacyte Inc Company Overview 32

5.12.1 Humacyte Inc Pipeline Products & Ongoing Clinical Trials Overview 32

5.13 Innovia LLC Company Overview 36

5.13.1 Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 36

5.14 LeMaitre Vascular Inc Company Overview 37

5.14.1 LeMaitre Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 37

5.15 Merit Medical Systems Inc Company Overview 39

5.15.1 Merit Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 39

5.16 Northwestern University Company Overview 40

5.16.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 40

5.17 Peca Labs, Inc. Company Overview 41

5.17.1 Peca Labs, Inc. Pipeline Products & Ongoing Clinical Trials Overview 41

5.18 PetVivo Holdings Inc Company Overview 42

5.18.1 PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 42

5.19 RegenaGraft Company Overview 43

5.19.1 RegenaGraft Pipeline Products & Ongoing Clinical Trials Overview 43

5.20 Secant Group LLC Company Overview 44

5.20.1 Secant Group LLC Pipeline Products & Ongoing Clinical Trials Overview 44

5.21 Terumo Aortic Company Overview 45

5.21.1 Terumo Aortic Pipeline Products & Ongoing Clinical Trials Overview 45

5.22 TTK Healthcare Ltd Company Overview 46

5.22.1 TTK Healthcare Ltd Pipeline Products & Ongoing Clinical Trials Overview 46

5.23 Universidad de Los Andes Company Overview 47

5.23.1 Universidad de Los Andes Pipeline Products & Ongoing Clinical Trials Overview 47

5.24 University of Louisville Company Overview 48

5.24.1 University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 48

5.25 University of Pittsburgh Company Overview 49

5.25.1 University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 49

5.26 VA Boston Healthcare System Company Overview 50

5.26.1 VA Boston Healthcare System Pipeline Products & Ongoing Clinical Trials Overview 50

5.27 VesselTek BioMedical LLC Company Overview 51

5.27.1 VesselTek BioMedical LLC Pipeline Products & Ongoing Clinical Trials Overview 51

5.28 VESSL Therapeutics Ltd Company Overview 52

5.28.1 VESSL Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview 52

5.29 W. L. Gore & Associates Inc Company Overview 53

5.29.1 W. L. Gore & Associates Inc Pipeline Products & Ongoing Clinical Trials Overview 53

5.30 Xeltis AG Company Overview 56

5.30.1 Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview 56

6 Vascular Grafts- Recent Developments 57

6.1 May 17, 2018: Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC 57

6.2 May 02, 2018: CryoLife Announces First Quarter 2018 Financial Results 57

6.3 Apr 27, 2018: Fit Biotech: Appointment of Tommi Holopainen as CFO and as a Member of the Management Team 58

6.4 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018 59

6.5 Apr 25, 2018: LeMaitre Q1 2018 Sales USD26.0mm (+8%), EPS USD0.19 (+17%) 61

6.6 Mar 28, 2018: MicroPort Scientific Announces 2017 Annual Results 61

6.7 Mar 27, 2018: MicroPort Scientific Announces Year Ended 31 December 2017 Financial Results 63

6.8 Mar 15, 2018: FIT Biotech's Review of Operations and Financial Statement 2017 published 64

6.9 Mar 07, 2018: CryoLife Reports Fourth Quarter and Full Year 2017 Results 64

6.10 Feb 21, 2018: LeMaitre Reports Net Income Of USD4.3mm In Q4 2017 65

6.11 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 66

6.12 Jan 23, 2018: Jonathan Vande Geest, University Of Pittsburg Has Received A NIH Grant To Construct A Biomeimetic, Small Diameter Vascular Graft 68

6.13 Jan 18, 2018: FIT Biotech's CEO to change-Erkki Pekkarinen appointed as a new CEO 68

6.14 Jan 18, 2018: FIT Biotech Oy Announces Senior Management Changes 69

6.15 Jan 16, 2018: Secant Group Develops the First Synthetic Regenerative Cardiovascular Graft 69

6.16 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 70

6.17 Oct 30, 2017: CryoLife Reports Third Quarter 2017 Results 70

6.18 Oct 26, 2017: LeMaitre Q3 2017 Sales USD24.8mm (+7%), Record EPS USD0.25 (+49%) 72

6.19 Oct 26, 2017: Boston Scientific Announces Results For Third Quarter 2017 72

6.20 Oct 25, 2017: Bard Announces Third Quarter Results 74

6.21 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary 75

6.22 Oct 02, 2017: Humacyte Awarded USD3.4 Million Contract Award from the U.S. Department of Defense 76

6.23 Oct 02, 2017: Jeffrey H. Burbank Joins CryoLife Board of Directors 76

6.24 Sep 26, 2017: ETR featured in peer-reviewed journal EuroIntervention 77

6.25 Sep 22, 2017: Xeltis CTO on the future of heart valve therapy at PCR London Valves 77

6.26 Sep 15, 2017: Fit Biotech Half-yearly Financial Report January 1-June 30, 2017 78

6.27 Sep 11, 2017: MPSC Achieves Substantial Growth in 1H 2017 Net Profit Increases 272.4% YOY 78

6.28 Aug 23, 2017: FIT Biotech Oy: FIT Biotech Board elected Erkki Pekkarinen to the Deputy Chairman of the Board 80

6.29 Aug 14, 2017: Governor McAuliffe Announces LifeNet Health to Invest USD12.25 million, Create 321 New Jobs in City of Virginia Beach 80

6.30 Aug 11, 2017: MPSC Issues Positive Profit Alert for 2017 1H Net Profit Expected to Increase 261% 81

6.31 Jul 27, 2017: LeMaitre Q2 2017 Record Sales USD25.8 mm (+15%), Record EPS USD0.23 (+69%) 81

6.32 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 82

6.33 Jul 24, 2017: MicroPort Attends EUROPACE-CARDIOSTIM 2017 84

6.34 Jul 24, 2017: CryoLife Reports Second Quarter 2017 Financial Results 84

6.35 Jul 20, 2017: Positive progression of ETR clinical trials at WCPCCS 86

6.36 Jul 07, 2017: MPSC New COO Glendy Wang on Board 86

6.37 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 86

7 Appendix 89

7.1 Methodology 89

7.2 About GlobalData 92

7.3 Contact Us 92

7.4 Disclaimer 92


List Of Figure

1.2 List of Figures

Figure 1: Vascular Grafts-Pipeline Products by Stage of Development 9

Figure 2: Vascular Grafts-Pipeline Products by Segment 10

Figure 3: Vascular Grafts-Pipeline Products by Territory 11

Figure 4: Vascular Grafts-Pipeline Products by Regulatory Path 12

Figure 5: Vascular Grafts-Pipeline Products by Estimated Approval Date 13

Figure 6: Vascular Grafts-Ongoing Clinical Trials 14


List Of Table

1.1 List of Tables

Table 1: Vascular Grafts-Pipeline Products by Stage of Development 9

Table 2: Vascular Grafts-Pipeline Products by Segment 10

Table 3: Vascular Grafts-Pipeline Products by Territory 11

Table 4: Vascular Grafts-Pipeline Products by Regulatory Path 12

Table 5: Vascular Grafts-Pipeline Products by Estimated Approval Date 13

Table 6: Vascular Grafts-Ongoing Clinical Trials 14

Table 7: Vascular Grafts Companies-Pipeline Products by Stage of Development 15

Table 8: Vascular Grafts-Pipeline Products by Stage of Development 17

Table 9: Ariste Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 18

Table 10: Drug Eluting Vascular Graft-Product Status 18

Table 11: Drug Eluting Vascular Graft-Product Description 18

Table 12: BioSurfaces, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19

Table 13: BioFunc-APC Vascular Graft-Product Status 19

Table 14: BioFunc-APC Vascular Graft-Product Description 19

Table 15: Cardiojustable LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 20

Table 16: Adjustable SPA Shunt-Product Status 20

Table 17: Adjustable SPA Shunt-Product Description 20

Table 18: Cardiovate Pipeline Products & Ongoing Clinical Trials Overview 21

Table 19: NeoVessel Vascular Graft-Product Status 21

Table 20: NeoVessel Vascular Graft-Product Description 21

Table 21: Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview 22

Table 22: Xenograft Implant-Peripheral Vascular Disease-Product Status 22

Table 23: Xenograft Implant-Peripheral Vascular Disease-Product Description 22

Table 24: CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview 23

Table 25: Synergraft Xenograft Vascular Graft-Product Status 23

Table 26: Synergraft Xenograft Vascular Graft-Product Description 23

Table 27: Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24

Table 28: Lifeline TEBV-Lower Limb-Product Status 24

Table 29: Lifeline TEBV-Lower Limb-Product Description 24

Table 30: LifeLine TEBV-Pediatric-Product Status 25

Table 31: LifeLine TEBV-Pediatric-Product Description 25

Table 32: DSM Biomedical BV Pipeline Products & Ongoing Clinical Trials Overview 26

Table 33: Small Diameter Vascular Graft-Product Status 26

Table 34: Small Diameter Vascular Graft-Product Description 26

Table 35: Eqalix Inc Pipeline Products & Ongoing Clinical Trials Overview 27

Table 36: CardioVessel-Product Status 27

Table 37: CardioVessel-Product Description 27

Table 38: LCL Graft-Product Status 28

Table 39: LCL Graft-Product Description 28

Table 40: FIT Biotech Oy Pipeline Products & Ongoing Clinical Trials Overview 29

Table 41: GTU X-Graft-Product Status 29

Table 42: GTU X-Graft-Product Description 29

Table 43: GTU X2-Graft-Product Status 30

Table 44: GTU X2-Graft-Product Description 30

Table 45: Gel-Del Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31

Table 46: VasoGraft-Product Status 31

Table 47: VasoGraft-Product Description 31

Table 48: Humacyte Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Table 49: HUMACYL-Peripheral Artery Disease-Product Status 32

Table 50: HUMACYL-Peripheral Artery Disease-Product Description 32

Table 51: HUMACYL Graft-Vascular Trauma-Product Status 33

Table 52: HUMACYL Graft-Vascular Trauma-Product Description 33

Table 53: Humacyte Inc-Ongoing Clinical Trials Overview 34

Table 54: HUMACYL-Peripheral Artery Disease-A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacytes Human Acellular Vessel for Use as a Vascular Bypass or Interposition Vessel in Patients with Limb-threatening Peripheral Arterial Trauma 35

Table 55: Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 36

Table 56: 4mm Vascular Graft-Product Status 36

Table 57: 4mm Vascular Graft-Product Description 36

Table 58: LeMaitre Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 37

Table 59: LifeSpan ePTFE Vascular Graft-Product Status 37

Table 60: LifeSpan ePTFE Vascular Graft-Product Description 38

Table 61: Merit Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 39

Table 62: Self-expanding Covered Stent Graft-Product Status 39

Table 63: Self-expanding Covered Stent Graft-Product Description 39

Table 64: Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 40

Table 65: ePTFE Graft-Peripheral Arterial Disease-Product Status 40

Table 66: ePTFE Graft-Peripheral Arterial Disease-Product Description 40

Table 67: Peca Labs, Inc. Pipeline Products & Ongoing Clinical Trials Overview 41

Table 68: exGraft-Product Status 41

Table 69: exGraft-Product Description 41

Table 70: PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 42

Table 71: Peripheral Vascular Graft-Product Status 42

Table 72: Peripheral Vascular Graft-Product Description 42

Table 73: RegenaGraft Pipeline Products & Ongoing Clinical Trials Overview 43

Table 74: RegenaVasc-Product Status 43

Table 75: RegenaVasc-Product Description 43

Table 76: Secant Group LLC Pipeline Products & Ongoing Clinical Trials Overview 44

Table 77: Regenerative Cardiovascular Graft-Product Status 44

Table 78: Regenerative Cardiovascular Graft-Product Description 44

Table 79: Terumo Aortic Pipeline Products & Ongoing Clinical Trials Overview 45

Table 80: Triplex Advanced Vascular Graft-Product Status 45

Table 81: Triplex Advanced Vascular Graft-Product Description 45

Table 82: TTK Healthcare Ltd Pipeline Products & Ongoing Clinical Trials Overview 46

Table 83: Chitra Vascular Graft-Product Status 46

Table 84: Chitra Vascular Graft-Product Description 46

Table 85: Universidad de Los Andes Pipeline Products & Ongoing Clinical Trials Overview 47

Table 86: SiSgraft-Product Status 47

Table 87: SiSgraft-Product Description 47

Table 88: University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 48

Table 89: Vascular Graft System-Product Status 48

Table 90: Vascular Graft System-Product Description 48

Table 91: University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 49

Table 92: Biomimetic Vascular Graft-Product Status 49

Table 93: Biomimetic Vascular Graft-Product Description 49

Table 94: VA Boston Healthcare System Pipeline Products & Ongoing Clinical Trials Overview 50

Table 95: SelfWrap-Product Status 50

Table 96: SelfWrap-Product Description 50

Table 97: VesselTek BioMedical LLC Pipeline Products & Ongoing Clinical Trials Overview 51

Table 98: VTek Graft-Product Status 51

Table 99: VTek Graft-Product Description 51

Table 100: VESSL Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview 52

Table 101: MultiGeneGraft-Product Status 52

Table 102: MultiGeneGraft-Product Description 52

Table 103: W. L. Gore & Associates Inc Pipeline Products & Ongoing Clinical Trials Overview 53

Table 104: GORE VIABAHN Endoprosthesis-Product Status 53

Table 105: GORE VIABAHN Endoprosthesis-Product Description 53

Table 106: W. L. Gore & Associates Inc-Ongoing Clinical Trials Overview 54

Table 107: GORE VIABAHN Endoprosthesis-Post-approval Study of the Gore Viabahn Endoprosthesis for the Treatment of In-stent Restenosis (ISR) in the Superficial Femoral Artery (SFA) 55

Table 108: GORE VIABAHN Endoprosthesis-Post-market Study: Evaluation of the GORE VIABAHN Endoprosthesis for the Treatment of Popliteal Artery Aneurysm 55

Table 109: GORE VIABAHN Endoprosthesis-The Utility of GP1101 Relative to Surgical Bypass in the Treatment of Femoral / Popliteal Arterial Symptomatic Peripheral Arterial Disease 55

Table 110: Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview 56

Table 111: Endogenous Tissue Restoration (ETR) Cardiovascular Graft-Product Status 56

Table 112: Endogenous Tissue Restoration (ETR) Cardiovascular Graft-Product Description 56

Table 113: Glossary 91

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Ariste Medical LLC, Drug Eluting Vascular Graft; BioSurfaces, Inc., BioFunc - APC Vascular Graft; Cardiojustable LLC (Inactive), Adjustable SPA Shunt; Cardiovate, NeoVessel Vascular Graft; Colorado Therapeutics, LLC, Xenograft Implant - Peripheral Vascular Disease; CryoLife Inc, Synergraft Xenograft Vascular Graft; Cytograft Tissue Engineering Inc (Inactive), Lifeline TEBV - Lower Limb; Cytograft Tissue Engineering Inc (Inactive), LifeLine TEBV - Pediatric; DSM Biomedical BV, Small Diameter Vascular Graft; Eqalix Inc, CardioVessel; Eqalix Inc, LCL Graft; FIT Biotech Oy, GTU X2-Graft; FIT Biotech Oy, GTU X-Graft; Gel-Del Technologies, Inc., VasoGraft; Humacyte Inc, HUMACYL - Peripheral Artery Disease; Humacyte Inc, HUMACYL Graft - Vascular Trauma; Innovia LLC, 4mm Vascular Graft; LeMaitre Vascular Inc, LifeSpan ePTFE Vascular Graft; Merit Medical Systems Inc, Self-expanding Covered Stent Graft; Northwestern University, ePTFE Graft - Peripheral Arterial Disease; Peca Labs, Inc., exGraft; PetVivo Holdings Inc, Peripheral Vascular Graft; RegenaGraft, RegenaVasc; Secant Group LLC, Regenerative Cardiovascular Graft; Terumo Aortic, Triplex Advanced Vascular Graft; TTK Healthcare Ltd, Chitra Vascular Graft; Universidad de Los Andes, SiSgraft; University of Louisville, Vascular Graft System; University of Pittsburgh, Biomimetic Vascular Graft; VA Boston Healthcare System, SelfWrap; VesselTek BioMedical LLC, VTek Graft; VESSL Therapeutics Ltd, MultiGeneGraft; W. L. Gore &; Associates Inc, GORE VIABAHN Endoprosthesis; Xeltis AG, Endogenous Tissue Restoration (ETR) Cardiovascular Graft


Companies

Ariste Medical LLC

BioSurfaces, Inc.

Cardiojustable LLC

Cardiovate

Colorado Therapeutics, LLC

CryoLife Inc

Cytograft Tissue Engineering Inc

DSM Biomedical BV

Eqalix Inc

FIT Biotech Oy

Gel-Del Technologies, Inc.

Humacyte Inc

Innovia LLC

LeMaitre Vascular Inc

Merit Medical Systems Inc

Northwestern University

Peca Labs, Inc.

PetVivo Holdings Inc

RegenaGraft

Secant Group LLC

Terumo Aortic

TTK Healthcare Ltd

Universidad de Los Andes

University of Louisville

University of Pittsburgh

VA Boston Healthcare System

VesselTek BioMedical LLC

VESSL Therapeutics Ltd

W. L. Gore & Associates Inc

Xeltis AG